ThePrint on MSN8h
2nd ‘living drug’ against blood cancer gets regulatory nod. All about Qartemi, made in India
Therapy will cost Rs 35 to 50 lakh. India sees around 1.20 lakh new blood cancer cases and over 70,000 deaths annually from ...
Artificial Intelligence in Oncology Market to Hit US$ 11.52 Billion by 2030 with 29.4% CAGR | MarketsandMarkets™.
The global AI in oncology market, valued at US$1.92 billion in 2023, is forecasted to grow at a robust CAGR of 29.4%, ...
The Morung Express10h
Immuneel launches affordable CAR T-cell therapy for non-Hodgkin’s Lymphoma in India
Immuneel, launched in 2019, initiated the trial on India’s first CAR T-cell therapy trial in 2022 for a novel autologous CD19 ...
Cell & gene therapy statrtup Immuneel unveils CAR-T cancer therapy in India
Immuneel Therapeutics, the start-up, backed by Kiran Mazumdar-Shaw, was the first in India to conduct CAR T-cell therapy ...
Immuneel’s internationally-benchmarked CAR-T cell therapy for Non-Hodgkin’s Lymphoma, is one-tenth US cost: CEO
Immuneel Therapeutics launches affordable CAR-T therapy Qartemi for B-cell Non-Hodgkin Lymphoma, aiming to revolutionize ...